هل الأرباح النقدية لـ Dermapharm Holding آمنة؟
Dermapharm Holding يزيد الأرباح منذ 4 سنوات.
خلال السنوات الـ10 الماضية، حققت Dermapharm Holding نموًا سنويًا بنسبة 0% خُفِّضَ.
على مدى 5 سنوات هبط التوزيع بنسبة 0 %.
يتوقع المحللون للسنة المالية الجارية نمواً بنسبة زيادة الأرباح% بمقدار ٥٫٦١٢.
Dermapharm Holding Aktienanalyse
ماذا يفعل Dermapharm Holding؟
Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich.
Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications.
The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products.
Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products.
Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women.
Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils.
Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products.
Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding هو واحد من الشركات الأكثر شعبية على Eulerpool.com.